Premium
ARLTS1 variants and melanoma risk
Author(s) -
Frank Bernd,
Meyer Peter,
Boettger Melanie Barbara,
Hemminki Kari,
Stapelmann Henrike,
Gast Andreas,
Schmitt Christina,
Kumar Rajiv,
Sergi Consolato,
Burwinkel Barbara
Publication year - 2006
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.22008
Subject(s) - melanoma , medicine , risk factor , oncology , tumor suppressor gene , breast cancer , case control study , cancer , suppressor , cancer research , carcinogenesis
Variants in the tumor suppressor gene ARLTS1 (ADP‐ribosylation factor‐like tumor‐suppressor gene 1) have been shown to influence familial cancer risk. Both Cys148Arg and Trp149Stop were associated with an increased risk of familial or high‐risk familial breast cancer, respectively. We studied the impact of these gene variants on melanoma risk, investigating 351 melanoma patients and 804 control subjects. While ARLTS1 Trp149Stop did not influence melanoma risk (OR = 0.83, 95% CI = 0.37–1.88, p = 0.65), Cys148Arg revealed a statistically significant association with an increased risk for heterozygous carriers (OR = 1.43, 95% CI = 1.05–1.95, p = 0.02). An additional risk enhancement, though statistically non‐significant, was observed in individuals with multiple melanomas (OR = 2.33, 95% CI = 0.87–6.26, p = 0.08). © 2006 Wiley‐Liss, Inc.